Kintara Therapeutics (STU:3DMA) Cash per Share : €2.89 (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintara Therapeutics Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Kintara Therapeutics's Cash per Share for the quarter that ended in Jun. 2024 was €2.89.

Kintara Therapeutics Cash per Share Historical Data

The historical data trend for Kintara Therapeutics's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintara Therapeutics Cash per Share Chart

Kintara Therapeutics Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Cash per Share

Get a 7-Day Free Trial

324.28

467.45

297.57

29.31

2.89

Kintara Therapeutics Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Cash per Share	Get a 7-Day Free Trial															29.31	4.05	2.08	3.70	2.89

Kintara Therapeutics Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Kintara Therapeutics's Cash per Share for the fiscal year that ended in Jun. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	4.56	/	1.58
	=	2.89

Kintara Therapeutics's Cash per Share for the quarter that ended in Jun. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	4.56	/	1.58
	=	2.89

Kintara Therapeutics (STU:3DMA) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Kintara Therapeutics Cash per Share Related Terms

Thank you for viewing the detailed overview of Kintara Therapeutics's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintara Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintara Therapeutics Inc (STU:3DMA) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

KTRA:USA 3DMA:Germany

Address

9920 Pacific Heights Boulevard, Suite 150, San Diego, CA, USA, 92121

Website

https://www.kintara.com

Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including the central nervous system, ovarian, and other solid tumors. The company operates within a single operating segment the research and development of cancer indications, and operates primarily in one geographic area, being North America.

Kintara Therapeutics Headlines

No Headlines